Navigation Links
Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
Date:9/23/2008

r and lead medical negotiator for FDA interactions for AIR(R) Insulin, Lilly's inhaled insulin program.

During its first five years of development, Dr. Muchmore was the sole physician on the Lilly inhaled insulin development effort and the AIR(R) Insulin team. He was responsible for designing and executing all of the early phase studies and he successfully advanced the program to Phase III. Dr. Muchmore's responsibilities at Lilly also included the evaluation of promising new technologies, which is how he became aware of Halozyme's proprietary insulin program and its recombinant human hyaluronidase enzyme technology. Prior to leading Lilly's inhaled insulin program, Dr. Muchmore served on the Evista Product Team for osteoporosis and breast cancer indications from 1995 to 1999 and as its Physician Group Leader from 1997 to 1999. He is the recipient of numerous awards for professional achievement, including the Eli Lilly Global Brand Development Team Leadership Award in 2007.

From 1982 to 1995, Dr. Muchmore was staff endocrinologist at the Scripps Clinic and Research Foundation, holding additional appointments as Clinical Assistant Professor of Medicine, UCSD, and Senior Physician, The Whittier Institute for Diabetes and Endocrinology. Dr. Muchmore also served as visiting endocrinologist at the Logan Heights Community Clinic in San Diego. He received his AB degree in Biological Sciences from Stanford University, his MD from UCSD, and initiated his internship and residency training in internal medicine at the University of Washington Affiliated Hospitals in Seattle, Washington. He finished his residency training in 1978 at the Martinez Veterans Hospital, affiliated with the University of California, Davis. Dr. Muchmore completed a Fellowship in Endocrinology and Metabolism, followed by Instructorship in Medicine, at University Hospital, Seattle in 1982.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
9. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... -- AmnioChor Inc., an early stage biotech startup based on ... that the Musculoskeletal Transplant Foundation of Edison ... seed round of development of the proprietary AmnioCept™ product ... AmnioChor,s technology allows cryopreservation of the amniotic membrane ... within those tissues. Amnion is a well-established source of ...
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE MKT: ... results will be released on Thursday, August 13, 2015, ... Time, Pfenex management will host a conference call to ... A press release outlining the financial results and business ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) ...
(Date:7/29/2015)... ... 29, 2015 , ... The third Medical Innovation Impact Index (MI3) Alert considers ... drug/device combinations. The current system received a score of 0 (range -10 to +10) ... (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
Breaking Biology Technology:The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... March 9 Campbell Alliance, the leading management ... industry, today announced that Joe Dillon has joined ... work closely with the Business Development Practice to ... and develop comprehensive strategies related to in- and ...
... 9 Human Genome Sciences, Inc. (Nasdaq: ... sponsor a conference call to discuss the results of ... alfa-2b) in patients with genotype 1 chronic hepatitis C.(Logo: ... by senior management and will be held on Monday, ...
... Nature Materials (09 March 2009) reveals how an ... Centre for Nanotechnology (LCN) at UCL have discovered a novel ... prove to be a step toward the development of new ... rain. , Although the structure of regular ice is ...
Cached Biology Technology:Campbell Alliance Hires Joe Dillon, Expands Business Development Practice 2Campbell Alliance Hires Joe Dillon, Expands Business Development Practice 3Human Genome Sciences to Sponsor Conference Call 2It's raining pentagons 2
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
(Date:7/2/2015)... , July 2, 2015 Fingerprint Cards ... FPC1035, FPC1145 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... sensors will be used by smartphone manufacturers in ... included in the communicated revenue guidance of approximately 2,200 MSEK ...
(Date:6/30/2015)... Pa. , June 30, 2015 ... the company as CEO to help further develop Genisphere,s ... wealth of partnering experience, having spent much of the ... including Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. ... focus on Technology and Biotech Corporate Finance. He graduated ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... 15, 2009 - (BRONX, NY) - The fact that they eat ... and other mammals are protected from the majority of fungal pathogens, ... University. The research, published in the Journal of ... the familiar 98.6o F or 37o C in people ...
... scientists have made a discovery that promises to deliver a ... effective in all mammals not just humans or another ... reads the biological ,barcodes, of infectious microbes such as food ... vaccine could be made to prevent a particular disease in ...
... study in the Oct. 15 issue of the Journal ... diet and exercise program may benefit obese patients with mild ... eliminate the condition. Results show improvement in typical ... of life and mood after the completion of a 16-week ...
Cached Biology News:Do 3 meals a day keep fungi away? 2Bug barcode readers hold out promise of universal vaccines 2Improved diet and exercise alone unlikely to cure obstructive sleep apnea in obese patients 2
(3-[125I]iodotyrosyl26)Galanin, porcine, 370 kBq, 10 uCi. Category: IODINE LIGANDS....
Homo sapiens postsynaptic protein CRIPT Antigen: Recombinant Protein...
Immunogen: Synthetic peptide based on the sequence: SPSSGPSLTADSMWR Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Biology Products: